Stock Market Reviews

CDTX (Cidara Therapeutics, Inc.) News

Get the latest news, insights, and market updates on CDTX (Cidara Therapeutics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• PFE- The Winner in the Metsera Bidding War
  Pfizer Inc. (PFE) finally topped Novo Nordisk (NVO) to buy Metsera after Novo raised its bid twice. Metsera’s crown jewel is MET-097i, a weekly and monthly injectable GLP-1 asset that’s about to begin Phase III development, writes John McCamant, editor of Medical Technology Stock Letter.
  Nov 19, 2025 - $CDTX
• Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything
  Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high-potential antiviral asset.
  Nov 18, 2025 - $CDTX
• Is Cidara Therapeutics Fairly Priced After Its 110% Surge and New Clinical Milestones?
  If you’re wondering whether Cidara Therapeutics is a hidden gem or just hype, you’re not alone. Let’s break down what’s driving all the buzz about this stock’s value. After an extraordinary climb of 110% in the past week and a jaw-dropping 698.2% rally year-to-date, Cidara’s recent price movements have definitely caught the attention of growth-focused investors and risk-watchers alike. Fueling the excitement, the company has been making headlines with its latest clinical milestones and...
  Nov 18, 2025 - $CDTX
• Merck Stock Rises as Heart-Drug Test Offers Hope for Post-Keytruda Era
  The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.
  Nov 18, 2025 - $CDTX
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks were decreasing late Monday afternoon with the NYSE Health Care Index and the Hea
  Nov 17, 2025 - $CDTX
• Goldman Sachs on brink of best M&A performance in 24 years
  Goldman Sachs is vying to capture its biggest share of the deals market in almost a quarter of a century, with Wall Street’s dominant investment...
  Nov 17, 2025 - $CDTX
• Cidara downgraded on Wall Street after Merck agrees to $9.2 billion buyout
  Investing.com -- Cidara Therapeutics was hit with broad downgrades after Merck agreed to buy the company for $221.50 a share in a deal valued at about $9.2 billion.
  Nov 17, 2025 - $CDTX
• Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck
  We recently published 10 Market Movers That Made Millionaires in a Week. Cidara Therapeutics Inc. (NASDAQ:CDTX) is one of the best-performing stocks of the past trading week. Cidara Therapeutics soared by more than 100 percent week-on-week, as investors repositioned portfolios following news that it is set to be acquired by Merck Co. for $9.2 billion. […]
  Nov 16, 2025 - $CDTX
• Cidara Therapeutics (CDTX) Skyrockets 105% on Merck $9.2-Billion Acquisition Bid
  We recently published Lackluster Market? Not for These 10 Soaring Stocks. Cidara Therapeutics, Inc. (NASDAQ:CDTX) is one of the best-performing stocks on Friday. Cidara Therapeutics soared to nearly a decade high on Friday, as investors gobbled up shares following news that it is set to be acquired by pharmaceutical giant Merck for $9.2 billion. At […]
  Nov 15, 2025 - $CDTX
• MSD bets big on flu antivirals with $9.2bn buyout of Cidara
  MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming patent expiry.
  Nov 14, 2025 - $CDTX